Literature DB >> 33489692

Quadruple gastrointestinal cancer with discordance of mismatch repair protein deficiency and microsatellite instability suggesting Lynch syndrome.

Satoshi Toyota1, Ryota Nakanishi1, Yu Miyashita1,2, Shinichiro Yoshino1, Yoshiaki Fujimoto1, Tomoko Jogo1, Qingjiang Hu1, Kentaro Hokonohara1, Yuichi Hisamatsu1, Koji Ando1, Yasue Kimura1, Eiji Oki1, Yoshinao Oda2, Masaki Mori1.   

Abstract

A 65-year-old woman with prior personal and family histories of cancer was admitted to our hospital for quadruple cancer. Preoperative endoscopy revealed a type 0-II gastric cancer (GC; gastric body), advanced type-II colon cancer (ascending colon), and early-stage recto-sigmoid colon cancers. We diagnosed her with Lynch syndrome (LS) per Amsterdam criteria, and performed distal gastrectomy, ileocecal resection and high anterior resection. Her pathological diagnoses were GC: well-to-poorly differentiated adenocarcinoma (AD, por2 > tub2) with signet-ring cells, ypT1b SM2; ascending colon cancer: AD with focal mucin products (tub2 > muc), SS; sigmoid colon cancer: AD (tub1), M; recto-sigmoid cancer: AD (tub1 > tub2), SM. Immunohistochemical tests revealed that all cancers lacked the MLH1/PMS2 protein. However, the three colon cancers were found to have high microsatellite instability (MSI); the GC was microsatellite stable (MSS). No recurrence or other cancers were observed for 30 months after surgery without adjuvant chemotherapy. As patients with LS may also develop MSS cancers, we should check for MSI in all LS cancers for proper treatment. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Lynch syndrome; Microsatellite instability; Quadruple cancer

Year:  2020        PMID: 33489692      PMCID: PMC7797393          DOI: 10.1007/s13691-020-00457-9

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  16 in total

1.  Classics in oncology. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. By Aldred Scott Warthin. 1913.

Authors: 
Journal:  CA Cancer J Clin       Date:  1985 Nov-Dec       Impact factor: 508.702

2.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

Authors:  Aurelien Marabelle; Dung T Le; Paolo A Ascierto; Anna Maria Di Giacomo; Ana De Jesus-Acosta; Jean-Pierre Delord; Ravit Geva; Maya Gottfried; Nicolas Penel; Aaron R Hansen; Sarina A Piha-Paul; Toshihiko Doi; Bo Gao; Hyun Cheol Chung; Jose Lopez-Martin; Yung-Jue Bang; Ronnie Shapira Frommer; Manisha Shah; Razi Ghori; Andrew K Joe; Scott K Pruitt; Luis A Diaz
Journal:  J Clin Oncol       Date:  2019-11-04       Impact factor: 44.544

3.  Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study.

Authors:  A Gylling; W M Abdel-Rahman; M Juhola; K Nuorva; E Hautala; H J Järvinen; J-P Mecklin; M Aarnio; P Peltomäki
Journal:  Gut       Date:  2007-01-31       Impact factor: 23.059

4.  Total abdominal colectomy is cost-effective in treating colorectal cancer in patients with genetically diagnosed Lynch Syndrome.

Authors:  Boxiang Jiang; Asya Ofshteyn; Jay J Idrees; Matthew Giglia; Carlos Gallego; Sharon L Stein; Emily Steinhagen
Journal:  Am J Surg       Date:  2019-03-16       Impact factor: 2.565

5.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

6.  Identification of Lynch syndrome among patients with colorectal cancer.

Authors:  Leticia Moreira; Francesc Balaguer; Noralane Lindor; Albert de la Chapelle; Heather Hampel; Lauri A Aaltonen; John L Hopper; Loic Le Marchand; Steven Gallinger; Polly A Newcomb; Robert Haile; Stephen N Thibodeau; Shanaka Gunawardena; Mark A Jenkins; Daniel D Buchanan; John D Potter; John A Baron; Dennis J Ahnen; Victor Moreno; Montserrat Andreu; Maurizio Ponz de Leon; Anil K Rustgi; Antoni Castells
Journal:  JAMA       Date:  2012-10-17       Impact factor: 56.272

Review 7.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).

Authors:  H F A Vasen; G Möslein; A Alonso; I Bernstein; L Bertario; I Blanco; J Burn; G Capella; C Engel; I Frayling; W Friedl; F J Hes; S Hodgson; J-P Mecklin; P Møller; F Nagengast; Y Parc; L Renkonen-Sinisalo; J R Sampson; A Stormorken; J Wijnen
Journal:  J Med Genet       Date:  2007-02-27       Impact factor: 6.318

8.  Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis.

Authors:  Salim S Malik; Mark P Lythgoe; Mark McPhail; Kevin J Monahan
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

9.  Molecular and Pathological Features of Gastric Cancer in Lynch Syndrome and Familial Adenomatous Polyposis.

Authors:  Mara Fornasarig; Raffaella Magris; Valli De Re; Ettore Bidoli; Vincenzo Canzonieri; Stefania Maiero; Alessandra Viel; Renato Cannizzaro
Journal:  Int J Mol Sci       Date:  2018-06-06       Impact factor: 5.923

10.  Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.

Authors:  Dung T Le; Tae Won Kim; Eric Van Cutsem; Ravit Geva; Dirk Jäger; Hiroki Hara; Matthew Burge; Bert O'Neil; Petr Kavan; Takayuki Yoshino; Rosine Guimbaud; Hiroya Taniguchi; Elena Elez; Salah-Eddin Al-Batran; Patrick M Boland; Todd Crocenzi; Chloe E Atreya; Yi Cui; Tong Dai; Patricia Marinello; Luis A Diaz; Thierry André
Journal:  J Clin Oncol       Date:  2019-11-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.